A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Latest Information Update: 27 May 2025
At a glance
- Drugs Cyclophosphamide (Primary) ; Dactinomycin (Primary) ; Filgrastim (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary) ; Vincristine (Primary) ; Vinorelbine (Primary) ; Cyclophosphamide; Mesna
- Indications Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 May 2025 Phase has been changed from phase I\II to II.
- 18 May 2025 Planned number of patients changed from 100 to 135.
- 23 Jan 2024 Planned initiation date changed from 1 Nov 2023 to 1 Feb 2024.